Journal article icon

Journal article

Clinical advances of hypoxia-activated prodrugs in combination with radiotherapy

Abstract:

With the increasing incidence of cancer worldwide, the need for specific, effective therapies is ever more urgent. One example of targeted cancer therapeutics is hypoxia-activated prodrugs (HAPs), also known as bioreductive prodrugs. These prodrugs are inactive in cells with normal oxygen levels but in hypoxic cells (with low oxygen levels) undergo chemical reduction to the active compound. Hypoxia is a common feature of solid tumors and is associated with a more aggressive phenotype and resi...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/j.ijrobp.2017.03.024

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MPLS
Department:
Chemistry
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MPLS
Department:
Chemistry
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
More from this funder
Funding agency for:
Hammond, E
Publisher:
Elsevier Publisher's website
Journal:
International Journal of Radiation: Oncology - Biology - Physics Journal website
Volume:
98
Issue:
5
Pages:
1183-1196
Publication date:
2017-03-22
Acceptance date:
2017-03-02
DOI:
EISSN:
1879-355X
ISSN:
0360-3016
Source identifiers:
686271
Pubs id:
pubs:686271
UUID:
uuid:6f75ec95-bc24-4ed3-af6b-29236a41a43c
Local pid:
pubs:686271
Deposit date:
2017-03-17

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP